Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06199479 · ClinicalTrials.gov registry record · Phase 1

Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies

A Phase 1 study of Brain Malignancies and Pseudoprogression, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
25
Enrollment target
1
Study location

NCT06199479: Recruiting Phase 1 study of Brain Malignancies and Pseudoprogression, sponsored by M.D. Anderson Cancer Center.

NCT06199479 is a Phase 1 study of Brain Malignancies and Pseudoprogression that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06199479, a Phase 1 study of Brain Malignancies and Pseudoprogression, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

To learn if advanced imaging methods can tell apart true progression (the disease has actually gotten worse) from pseudoprogression (the disease appears to have gotten worse, but it actually has not).

Primary Outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

Interventions

  • PROCEDURE Biopsy
  • PROCEDURE MRI Scan
  • PROCEDURE CT Scan

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2024-06-04
Est. Completion 2027-10-31
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What NCT06199479 shows while recruiting

NCT06199479 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).

The record links to 2 conditions, with Brain Malignancies appearing as the primary indexed condition, and to 3 interventions - of which Biopsy is the first listed.

NCT06199479 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06199479 about?

NCT06199479 is a clinical study titled "Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies". To learn if advanced imaging methods can tell apart true progression (the disease has actually gotten worse) from pseudoprogression (the disease appears to have gotten worse, but it actually has not).

What is the current status of trial NCT06199479?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2024-06-04. Estimated completion is 2027-10-31.

What conditions does trial NCT06199479 study?

This clinical trial studies the following conditions: Brain Malignancies, Pseudoprogression.

What interventions are being tested in trial NCT06199479?

The interventions under investigation include: Biopsy (PROCEDURE), MRI Scan (PROCEDURE), CT Scan (PROCEDURE).

Who is sponsoring clinical trial NCT06199479?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06199479 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT06199479's enrollment target sits among peer trials

25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06199479, the US trial registry maintained by the National Library of Medicine. NCT06199479 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.